Brainsway announces new data on noninvasive way to treat depression

BrainsWay (BWAY) unveiled new clinical data showing a faster, noninvasive way to treat depression without compromising the efficacy of one of psychiatry’s most impactful treatments. The milestone advances BrainsWay’s brain health vision and sets the stage for a neuromodulation platform that transforms lives. Two new peer-reviewed manuscripts in Brain Stimulation found that BrainsWay’s exclusive FDA-cleared SWIFT accelerated Deep Transcranial Magnetic Stimulation protocol for the treatment of Major Depressive Disorder achieved comparable remission and response rates when compared to the traditional standard protocol. The accelerated protocol reduces the traditional 20-visit acute treatment phase to just 6 half days, followed by weekly maintenance visits for 4 weeks.